ImmunoPrecise Antibodies (IPA) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPA vs. ZYBT, CTMX, DSGN, MBX, BNTC, IMAB, UPXI, RCKT, ABEO, and CGCShould you be buying ImmunoPrecise Antibodies stock or one of its competitors? The main competitors of ImmunoPrecise Antibodies include Zhengye Biotechnology (ZYBT), CytomX Therapeutics (CTMX), Design Therapeutics (DSGN), MBX Biosciences (MBX), Benitec Biopharma (BNTC), I-Mab (IMAB), Upexi (UPXI), Rocket Pharmaceuticals (RCKT), Abeona Therapeutics (ABEO), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry. ImmunoPrecise Antibodies vs. Its Competitors Zhengye Biotechnology CytomX Therapeutics Design Therapeutics MBX Biosciences Benitec Biopharma I-Mab Upexi Rocket Pharmaceuticals Abeona Therapeutics Canopy Growth ImmunoPrecise Antibodies (NASDAQ:IPA) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability. Is IPA or ZYBT more profitable? Zhengye Biotechnology has a net margin of 0.00% compared to ImmunoPrecise Antibodies' net margin of -122.10%. Zhengye Biotechnology's return on equity of 0.00% beat ImmunoPrecise Antibodies' return on equity.Company Net Margins Return on Equity Return on Assets ImmunoPrecise Antibodies-122.10% -40.62% -22.19% Zhengye Biotechnology N/A N/A N/A Does the media favor IPA or ZYBT? In the previous week, Zhengye Biotechnology had 2 more articles in the media than ImmunoPrecise Antibodies. MarketBeat recorded 3 mentions for Zhengye Biotechnology and 1 mentions for ImmunoPrecise Antibodies. Zhengye Biotechnology's average media sentiment score of 0.95 beat ImmunoPrecise Antibodies' score of 0.63 indicating that Zhengye Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment ImmunoPrecise Antibodies Positive Zhengye Biotechnology Positive Do analysts recommend IPA or ZYBT? ImmunoPrecise Antibodies presently has a consensus price target of $4.00, indicating a potential upside of 90.93%. Given ImmunoPrecise Antibodies' stronger consensus rating and higher possible upside, analysts clearly believe ImmunoPrecise Antibodies is more favorable than Zhengye Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunoPrecise Antibodies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Zhengye Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable valuation and earnings, IPA or ZYBT? Zhengye Biotechnology has higher revenue and earnings than ImmunoPrecise Antibodies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunoPrecise Antibodies$17.59M0.00-$21.69M-$0.68N/AZhengye Biotechnology$25.53M18.48$1.55MN/AN/A Do institutionals & insiders believe in IPA or ZYBT? 6.7% of ImmunoPrecise Antibodies shares are held by institutional investors. 6.8% of ImmunoPrecise Antibodies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryZhengye Biotechnology beats ImmunoPrecise Antibodies on 7 of the 12 factors compared between the two stocks. Get ImmunoPrecise Antibodies News Delivered to You Automatically Sign up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPA vs. The Competition Export to ExcelMetricImmunoPrecise AntibodiesMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$96.68M$2.09B$5.70B$10.27BDividend YieldN/AN/A5.72%4.60%P/E Ratio-3.0834.9775.8126.51Price / SalesN/A10.06492.95166.26Price / CashN/A58.5825.8129.90Price / BookN/A11.6812.836.31Net Income-$21.69M-$63.67M$3.28B$270.12M7 Day PerformanceN/A-2.22%0.24%2.04%1 Month Performance4.75%1.69%4.59%6.25%1 Year Performance284.40%34.87%68.69%25.50% ImmunoPrecise Antibodies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPAImmunoPrecise Antibodies2.621 of 5 starsN/A$4.00+∞+212.7%$96.68M$17.59M-3.0880Gap UpZYBTZhengye BiotechnologyN/A$8.15-0.5%N/AN/A$386.29M$186.36M0.00278High Trading VolumeCTMXCytomX Therapeutics4.1399 of 5 stars$2.18-4.4%$5.75+163.8%+61.8%$376M$138.10M3.89170News CoveragePositive NewsDSGNDesign Therapeutics0.2532 of 5 stars$5.82-9.8%N/A+5.8%$367.32MN/A-5.2040Positive NewsMBXMBX Biosciences2.8203 of 5 stars$10.90-5.6%$37.63+245.2%N/A$366.18MN/A-2.4036Positive NewsBNTCBenitec Biopharma1.6837 of 5 stars$13.84-0.5%$26.00+87.9%+68.1%$365.14M$80K-9.1720Positive NewsAnalyst ForecastIMABI-Mab2.6504 of 5 stars$4.27-2.5%$7.00+63.9%+241.5%$357.67M$3.89M0.00380UPXIUpexi3.3478 of 5 stars$5.66-6.3%$15.50+173.9%+62.6%$355.69M$26M0.00130Short Interest ↓RCKTRocket Pharmaceuticals4.7798 of 5 stars$3.26-0.6%$16.73+413.3%-83.6%$353.92MN/A-1.30240Short Interest ↑ABEOAbeona Therapeutics4.128 of 5 stars$6.70-2.8%$19.50+191.0%+2.5%$353.31M$3.50M9.5790Positive NewsCGCCanopy Growth1.106 of 5 stars$1.35-7.5%N/A-71.0%$350.18M$225.65M-0.453,150News CoveragePositive NewsOptions Volume Related Companies and Tools Related Companies Zhengye Biotechnology Alternatives CytomX Therapeutics Alternatives Design Therapeutics Alternatives MBX Biosciences Alternatives Benitec Biopharma Alternatives I-Mab Alternatives Upexi Alternatives Rocket Pharmaceuticals Alternatives Abeona Therapeutics Alternatives Canopy Growth Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPA) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredSean Hannity: Help Protect Your RetirementThis Guide to retirement protection has helped thousands protect over $3 billion dollars in retirement savings...Goldco Precious Metals | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoPrecise Antibodies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoPrecise Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
